Novavax (NASDAQ:NVAX) is up 3% premarket on modest volume in response to the publication of a peer-reviewed letter in The New England Journal of Medicine detailing the results from a Phase 1/2 clinical trial evaluating seasonal flu vaccine NanoFlu compared to the leading egg-based high-dose vaccine in older adults.
The letter provides additional data from the announcement made in late February.
NanoFlu produced antibody titers 28-64% against the homologous and four generations of drifted wild-type A (H3N2) influenza strains and higher antibody titers against the homologous A (H1N1) strain and comparable responses against the homologous B/Brisbane strain.
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle flu vaccine produced by the company's SF9 insect cell baculovirus system. It uses HA amino acid protein sequences that are virtually the same as the wild types. It also contains the adjuvant Matrix-M.
Now read: Novavax: All Eyes On Q1 2019 »